Navigation Links
Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
Date:5/22/2013

May 22, 2012 (Hackensack, NJ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

"I'm excited to bring together some of the nation's top immunology experts to review the latest developments and implications of cell therapies in oncology, both in solid and liquid tumors," said Andre Goy M.D., Cancer Center Director, and Chief of lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "This will provide an opportunity to see where the field is going and discuss some of the mechanisms and applications of T-cell manipulation as a promising tool against a number of cancers. The preliminary results seen with these modified T-cells will likely be revolutionary in the treatment of cancer".

The conference, titled "Cell Therapy and Interventional Immunology: Current Developments and Implications", is designed for hematologists, oncologists, physicians, and medical professionals. Given the enormous impact and growing interest in those therapies, the conference will also be offered to patients and caregivers through live online streaming. Speakers will cover the biology and manufacturing aspects of the chimeric antigenic receptor (CAR) modified T-cells as well as other manipulation of T-cells and the immune system, which for the first time, seem to be translating into impressive activity in the clinic.

The conference speakers and presentations include:

  • Catherine Bollard, MBChB, M.D., Professor of Pediatrics, Medicine, and Pathology & Immunology, Texas Children's Cancer Center, Baylor College of Medicine: Anti-EBV T-Cells and CAR T-Cells and Their Applications in Hematological Malignancies
  • Renier J. Brentjens, M.D., Ph.D., Leukemia Service, Memorial Sloan-Kettering Cancer Center: CAR Modified T-Cells for the Treatment of Cancer: Preclinical and Clinical Outcomes
  • Daniel H. Fowler M.D., Senior Investigator, Center for Cancer Research. National Cancer Institute: TH-2 Amplification and Other strategies to Reduce GVHD and Improve Outcome in Allogeneic Transplantations.
  • James N. Kochenderfer, M.D., Assistant Clinical Investigator, Center for cancer Research, National Cancer Institute: Autologous and Donor Derived Anti-CD19 CAR T-Cells Applications in non-Hodgkin Lymphoma and CLL
  • Cameron J. Turtle, M.D., Ph.D., Acting Instructor, University of Washington and Research Associate, Fred Hutchinson Cancer Research Center: Engineered Antigen Presenting Cells and T-Cells for Anti-Cancer Therapy

"Conferences such as this help physicians, medical professionals, as well as patients and caregivers to gain a better understanding of promising new treatment options, resulting in better clinical outcomes," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, "John Theurer Cancer Center is committed to providing these conferences to improve patient care and education."


'/>"/>

Contact: Amy Leahing
ALeahing@hackensackumc.org
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
2. Mirena IUD Lawyers at Gilman Law LLP, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Anticipates Progress in Newly Established Mirena Federal Litigation
3. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
4. Study evaluates effect of different supplements on reducing risk of progression to advanced AMD
5. Nina Brown Launches New Website for Spiritual Progressives
6. Despite superbug crisis, progress in antibiotic development alarmingly elusive
7. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
8. New findings on the brains immune cells during Alzheimers disease progression
9. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
10. Progressive Dental Marketing Is Bringing Online Dental Marketing to Washington for Dental Professionals Specializing in Laser Dentistry and Dental Implants
11. Progressive Dental Marketing Is Bringing Online Dental Marketing to Vancouver, B.C. for Dental Professionals Specializing in Laser Dentistry and Dental Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: